Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piers Blombery

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Leukemia & Lymphoma|September 20, 2019
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative diseasePiers Blombery
Blood|June 4, 2026
T-ALL: the origin storyPiers Blombery
Blood|April 22, 2021
Defining double-hit lymphoma in the clinicPiers Blombery, Stephen Lade
Journal of Blood Medicine|February 14, 2014
Management of thrombotic thrombocytopenic purpura: current perspectivesPiers Blombery, Marie Scully
Leukemia & Lymphoma|November 9, 2018
What does good FISHing look like in MDS?Meaghan Wall, Piers Blombery
Leukemia & Lymphoma|November 14, 2022
Matching phenotypes through mismatching genomicsLucy C Fox, Piers Blombery
Leukemia & Lymphoma|August 21, 2018
Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapyPiers Blombery, Sarah-Jane Dawson
Leukemia & Lymphoma|December 8, 2017
The price of success-health economics of personalized diffuse large B-cell lymphoma treatmentPiers Blombery, Jennifer Lickiss, Michael Dickinson
Blood|January 14, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsConstantine S Tam, Shalini Balendran, Piers Blombery
Leukemia & Lymphoma|September 20, 2013
De novo B-cell prolymphocytic leukemia with central nervous system involvementMaciek Tatarczuch, Piers Blombery, John F Seymour
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|September 20, 2019
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative diseasePiers Blombery
Blood|June 4, 2026
T-ALL: the origin storyPiers Blombery
Blood|April 22, 2021
Defining double-hit lymphoma in the clinicPiers Blombery, Stephen Lade
Journal of Blood Medicine|February 14, 2014
Management of thrombotic thrombocytopenic purpura: current perspectivesPiers Blombery, Marie Scully
Leukemia & Lymphoma|November 9, 2018
What does good FISHing look like in MDS?Meaghan Wall, Piers Blombery
Leukemia & Lymphoma|November 14, 2022
Matching phenotypes through mismatching genomicsLucy C Fox, Piers Blombery
Leukemia & Lymphoma|August 21, 2018
Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapyPiers Blombery, Sarah-Jane Dawson
Leukemia & Lymphoma|December 8, 2017
The price of success-health economics of personalized diffuse large B-cell lymphoma treatmentPiers Blombery, Jennifer Lickiss, Michael Dickinson
Blood|January 14, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsConstantine S Tam, Shalini Balendran, Piers Blombery
Leukemia & Lymphoma|September 20, 2013
De novo B-cell prolymphocytic leukemia with central nervous system involvementMaciek Tatarczuch, Piers Blombery, John F Seymour
Pageof 16